Given that authorised in 2014, tucidinostat was considered as a second-line and subsequent therapy for PTCL patients in China. Scientific trials and preclinical scientific tests in numerous hematological malignancies and stable tumors is in progress. , 2008). Tucidinostat has been used in clinical trials to improve the therapeutic efficacy of https://peterj655vhr7.webdesign96.com/profile